• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biological research for nursing >Variations in COMT and NTRK2 Influence Symptom Burden in Women Undergoing Breast Cancer Treatment
【24h】

Variations in COMT and NTRK2 Influence Symptom Burden in Women Undergoing Breast Cancer Treatment

机译：COMT和NTRK2的变异影响患有乳腺癌治疗的女性的症状负担

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Women with breast cancer frequently report distressing symptoms during and after treatment that can significantly erode quality of life (QOL). Symptom burden among women with breast cancer is of complex etiology and is likely influenced by disease, treatment, and environmental factors as well as individual genetic differences. The purpose of the present study was to examine the relationships between genetic polymorphisms within Neurotrophic tyrosine kinase receptor 1 (NTRK1), Neurotrophic tyrosine kinase receptor 2 (NTRK2), and catechol-O-methyltransferase (COMT) and patient symptom burden of QOL, pain, fatigue, anxiety, depression, and sleep disturbance before, during, and after treatment for breast cancer in a subset of participants (N = 51) in a randomized clinical trial of a novel symptom-management modality for women with breast cancer undergoing chemotherapy. Patients were recruited at the time of initial breast cancer diagnosis and completed all survey measures at the time of recruitment, after the initiation of treatment (surgery and/or chemotherapy), and then following treatment conclusion. Multiple linear regression analyses revealed significant associations between NTRK2 and COMT single nucleotide polymorphism (SNP) genotype and symptom burden. Two COMT variants were associated with the specific symptoms of anxiety and QOL measures prior to the initiation of chemotherapy as well as pain interference and severity during and after treatment. Genotype at the NTRK2 SNP rs1212171 was associated with both sleep disturbance and fatigue. These findings, while exploratory, indicate that the genotypes of NTRK2 and COMT may contribute to relative risk for symptom burden during and shortly after the period of chemotherapy in women with early stage breast cancer.
机译：乳腺癌的妇女经常在治疗期间和后常常报告令人痛苦的症状，这可以显着侵蚀生活质量（QOL）。患有乳腺癌的症状负担是复杂的病因，可能受到疾病，治疗和环境因素以及个体遗传差异的影响。本研究的目的是检查神经营养酪氨酸激酶受体1（NTRK1）内遗传多态性之间的关系，神经营养酪氨酸激酶受体2（NTRK2）和儿茶酚-O-甲基转移酶（COMT）和患者症状的QOL，疼痛在进行化疗的新症状 - 管理态度的随机临床试验中，乳腺癌前，期间和后，期间和之后，期间和之后和睡眠扰动。在初始乳腺癌诊断时招募患者，并在招聘时完成所有调查措施，在治疗（手术和/或化疗）开始后，然后进行治疗结论。多元线性回归分析显示NTRK2和COMT单核苷酸多态性（SNP）基因型和症状负担之间的显着关联。在开始化疗之前，两种COMT变体与焦虑和QOL测量的特定症状相关，以及治疗期间和后和后的疼痛干扰和严重程度。 NTRK2 SNP RS121212171的基因型与睡眠扰动和疲劳均相关。这些发现在探索性的同时表明NTRK2和COMT的基因型可能会导致患有早期乳腺癌的女性化疗期间和不久的症状负担的相对风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号